These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 19337227)

  • 1. Calcium channel blocker-induced chylous ascites in peritoneal dialysis.
    Tsao YT; Chen WL
    Kidney Int; 2009 Apr; 75(8):868. PubMed ID: 19337227
    [No Abstract]   [Full Text] [Related]  

  • 2. Dihydropyridine type calcium channel blocker-induced turbid dialysate in patients undergoing peritoneal dialysis.
    Yoshimoto K; Saima S; Nakamura Y; Nakayama M; Kubo H; Kawaguchi Y; Nishitani H; Nakamura Y; Yasui A; Yokoyama K; Kuriyama S; Shirai D; Kugiyama A; Hayano K; Fukui H; Horigome I; Amagasaki Y; Tsubakihara Y; Kamekawa T; Ando R; Tomura S; Okamoto R; Miwa S; Koyama T; Echizen H
    Clin Nephrol; 1998 Aug; 50(2):90-3. PubMed ID: 9725779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Possible role of Lercanidipine in Chiloperitoneum occurrence in CAPD: a case-report].
    Nicotera R; Chiarella S; Placida G; De Paola L; D'Onofrio G; Panzino MT; Panzino A; Mileti S; Pinciaroli AR; Coppolino G
    G Ital Nefrol; 2018 Jul; 35(4):. PubMed ID: 30035445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical case: Peritoneal dialysis patient with cloudy peritoneal fluid following administration of calcium antagonists.
    Viñolo López MC; Gutiérrez Rivas PC; Liébana Cañada A; Gil Cunquero JM; Merino García E
    Nefrologia; 2011; 31(5):624. PubMed ID: 21959742
    [No Abstract]   [Full Text] [Related]  

  • 5. Lercanidipine-induced chylous ascites: Case report and literature review.
    Basualdo JE; Rosado IA; Morales MI; Fernández-Ros N; Huerta A; Alegre F; Landecho MF; Lucena JF
    J Clin Pharm Ther; 2017 Oct; 42(5):638-641. PubMed ID: 28485829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Manidipine hydrochloride-induced chyloperitoneum in a patient with systemic lupus erythematosus.
    Tanabe M; Iwata H; Kinoshita M; Sumiya M; Saima S
    Clin Nephrol; 1999 Mar; 51(3):195-6. PubMed ID: 10099897
    [No Abstract]   [Full Text] [Related]  

  • 7. Calcium Channel Blocker-Associated Chyloperitoneum in Patients Receiving Peritoneal Dialysis: A Systematic Review.
    Kim S; Yu YM; Kwon J; Yoo H; Jung SH; Lee E
    Int J Environ Res Public Health; 2019 Apr; 16(8):. PubMed ID: 31013922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Don't judge the book by its cover….
    Pasquinucci E; Esposito V; Sileno G; Colucci M; Arazzi M; Esposito C
    J Nephrol; 2021 Jun; 34(3):913-914. PubMed ID: 33683677
    [No Abstract]   [Full Text] [Related]  

  • 9. Lercanidipine-induced chyloperitoneum in patients on peritoneal dialysis.
    Yang WS; Huang JW; Chen HW; Tsai TJ; Wu KD
    Perit Dial Int; 2008; 28(6):632-6. PubMed ID: 18981394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Azelnidipine-induced chyloperitoneum in a patient with microscopic polyangiitis.
    Yamamoto T; Matsuda J; Kadoya H; Namba T; Takeji M; Yamauchi A
    Clin Exp Nephrol; 2010 Oct; 14(5):496-500. PubMed ID: 20556459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regarding 'Calcium channel blocker-induced chylous ascites in peritoneal dialysis'.
    Graice R; Bargman JM
    Kidney Int; 2010 Jan; 77(2):165; author reply 165. PubMed ID: 20040923
    [No Abstract]   [Full Text] [Related]  

  • 12. [What chance is there that the patient will be treated!].
    Grandel B; Rossi P; Bagneres D; Demoux AL; Aissi K; Bonin-Guillaume S; Frances Y; Coutant G
    Rev Med Interne; 2005 Jul; 26 Suppl 2():S206-7. PubMed ID: 16129147
    [No Abstract]   [Full Text] [Related]  

  • 13. Preservation of renal function: the spectrum of effects by calcium channel blockers.
    Selgas R
    Nephrol Dial Transplant; 1998 Sep; 13(9):2415-6. PubMed ID: 9761540
    [No Abstract]   [Full Text] [Related]  

  • 14. Aliskiren-induced chyloperitoneum in a patient on peritoneal dialysis.
    Saka Y; Tachi H; Sakurai H; Tawada M; Sawai A; Shimamura Y; Mizuno M; Maruyama S; Matsuo S; Ito Y
    Perit Dial Int; 2012; 32(1):111-3. PubMed ID: 22302930
    [No Abstract]   [Full Text] [Related]  

  • 15. Dihydropyridine calcium channel blockers: a rare and reversible cause of hepatotoxicity with cholestasis in a CAPD patient.
    Basile C; Mascia E
    Nephrol Dial Transplant; 1999 Nov; 14(11):2776-7. PubMed ID: 10534534
    [No Abstract]   [Full Text] [Related]  

  • 16. [Chylous ascites in 12 patients undergoing peritoneal dialysis].
    Poux JM; Bénévent D; Guiserix J; Le Meur Y; Lagarde C; Leroux-Robert C
    Nephrologie; 1994; 15(3):201-5. PubMed ID: 7969712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Octreotide therapy for chylous ascites in a chronic dialysis patient.
    Lee PH; Lin CL; Lai PC; Yang CW
    Nephrology (Carlton); 2005 Aug; 10(4):344-7. PubMed ID: 16109079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A drug-induced turbid peritoneal dialysate in five patients treated with continuous ambulatory peritoneal dialysis.
    Yoshimoto K; Saima S; Echizen H; Nakamura Y; Ishizaki T
    Clin Nephrol; 1993 Aug; 40(2):114-7. PubMed ID: 8222367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chylous ascites in a patient treated with intermittent peritoneal dialysis.
    Humayun HM; Daugirdas JT; Ing TS; Leehey DJ; Gandhi VC; Popli S
    Artif Organs; 1984 Aug; 8(3):358-60. PubMed ID: 6477204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chylous ascites: an unusual complication of peritoneal dialysis].
    DE Paula A; Jimeno A; Largo ME; Gago P; Díez JL; Bustamante J
    Rev Clin Esp; 1975 Nov; 139(4):333-8. PubMed ID: 1208913
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.